Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027969 · ClinicalTrials.gov registry record · Phase 4
Metabolic Surgery for Atrial Fibrillation Elimination
A Phase 4 study, sponsored by Ali Aminian.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT07027969 is a Phase 4 study that has not yet begun recruiting, run by Ali Aminian. The registered enrollment target is 100 participants.
The verdict
NCT07027969, a Phase 4 study, has not yet begun recruiting, sponsored by Ali Aminian.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
Interventions
- PROCEDURE Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- DRUG Anti-Obesity Medication (AOM) treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-11-01 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07027969
The ClinicalTrials.gov registry entry for NCT07027969 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ali Aminian, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Roux-en-Y Gastric Bypass or Sleeve Gastrectomy is the first listed.
NCT07027969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07027969 about?
NCT07027969 is a clinical study titled "Metabolic Surgery for Atrial Fibrillation Elimination". Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension...
What is the current status of trial NCT07027969?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-11-01. Estimated completion is 2030-03-31.
What interventions are being tested in trial NCT07027969?
The interventions under investigation include: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy (PROCEDURE), Anti-Obesity Medication (AOM) treatment (DRUG).
Who is sponsoring clinical trial NCT07027969?
This trial is sponsored by Ali Aminian, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.